Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

TARA·NASDAQ

$4.22

-1.2%
HealthcareBiotechnology

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$162.85M
EPS-1.3400
P/E Ratio-3.15
Earnings Date07/30/2026

tara

Common Stock

Last Annual Value

54.00K

3-Year CAGR

70%

5-Year CAGR

37%

10-Year CAGR

13%

Protara Therapeutics, Inc.

Protara Therapeutics, Inc. Competitors Analysis of Common Stock

TARA · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
54.00K
70.0%37.5%12.3% 
16.00K
47.4%-19.7%-0.7%
2.00K
N/A-30.7%-7.7%
64.65K
30.2%19.7%N/A
63.00K
11.9%14.5%N/A
5.00K
0.0%0.0%N/A
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
28.00K
36.5%20.5%N/A
6.00K
14.5%-87.0%N/A
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
9.00K
8.7%8.4%8.4%
OABI logo
OmniAb, Inc.
NASDAQ:OABI
14.00K
5.3%N/AN/A
3.51M
25.3%19.2%17.3%
Protara Therapeutics, Inc.

Protara Therapeutics, Inc. Fair Value Envelope

TARA · NASDAQ

Our analysis suggests that TARA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.22, this represents a potential HIDDEN relative to our calculated worth for Protara Therapeutics, Inc..

Intrinsic Value
Current Price: $4.22